Table 3

Study outcomes

Author	Year	Main outcomes	Significance	Level of evidence	Adverse events
Lee et al 36	2015	VAS (0–100) at 6, 12, 24 and 52 weeks	p<0.001	4	6 cases of mild swelling with spontaneous resolution within 2 weeks, 2 cases of joint effusion after 1 month, resolved within 1 months, not significant. 1 case of delayed elbow pain treated with tramadol and acetaminophen
		Modified mayo elbow performance index (MEPI)	p<0.001
		Largest defect area of common extensor origin tendon	p<0.001 (longitudinal and transverse)
Pascual-Garrido et al 41	2012	Tegner	p=0.0061	4	Not reported
		Lysholm	p=0.1043
		IKDC	p=0.047
		KOOS
		Pain	p=0.2399
		Symptoms	p=0.0086
		ADL	p=0.0246
		Sport	p=0.0078
		QOL	p=0.0825
		SF-12
		Mental	p=0.5589
		Physical	p=0.438
		Ultrasound evaluation	NA. All patients had grade 2–3 before inoculation. 6/9 had grade 1 after 6 months, one patient had grade 3
Hernigou et al 35	2014	MRI assessment of cuff healing:		4	Not reported
		Retears confirmed by MRI after 10 years Intervention:	p<0.05 BMSC 6/45 vs control 25/45
		No change of MRI healing grade after 10 years:	NA BMSC 34/45 vs control 6/45 2.2
		Mean cells success versus no success (retear):
		Bone marrow mononuclear cells	p<0.01 Success: 4200±1900/cm³ vs no success: 1500±1200/cm³
		Progenitor cells	p<0.01 Success: 54 000+23 000/cm³ vs no success: 14000±9000/cm³
		Non-healing in the first 6 months:	NA 0/45 intervention vs 8/45 control
Ellera Gomez et al 34	2012	UCLA score	NA, increase from 12 to 31	4	Not reported
Ellera Gomez et al 34	2012	MRI analysis	NA, 14 cases of full tendon integrity, 8/14 low signal intensity along supraspinatus, 11/14 high signal artefact at the bursal and tendon, 6/14 high signal intensity zone at the critical zone	4	Not reported

IKDC, International knee documentation committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; NA, not available or applicable; SF-12, short form health survey 12; UCLA score, University of California at Los Angeles Shoulder rating scale; VAS, visual analogue scale.